Prostate Cancer: Understanding Risk, Detection, and Integrative Support Strategies

Meta Description: Prostate cancer is the most common cancer in American men. Learn about risk factors, PSA screening, treatment options, and evidence-based integrative strategies to support prostate health.

Introduction

Prostate cancer is the most commonly diagnosed cancer in American men (excluding skin cancer) and the second leading cause of cancer death in men, after lung cancer. Yet it is also one of the most survivable cancers when detected early — with a near-100% 5-year survival rate for localized disease.

Understanding prostate cancer means navigating a complex landscape: a disease that ranges from slow-growing tumors that may never require treatment to aggressive cancers that spread rapidly. This article explores the biology, risk factors, screening controversies, treatment options, and the growing evidence for integrative approaches to prostate health.

What Is Prostate Cancer?

The prostate is a walnut-sized gland in men located below the bladder and in front of the rectum. It produces seminal fluid that nourishes and transports sperm. Prostate cancer develops when cells in the prostate gland begin to grow uncontrollably.

Over 95% of prostate cancers are adenocarcinomas — cancers arising from glandular cells. Prostate cancers are graded using the Gleason score (now reported as Grade Groups 1–5), which reflects how abnormal the cancer cells look under a microscope and predicts aggressiveness.

How Common Is It?

• Approximately 288,000 new cases diagnosed annually in the U.S.
• Lifetime risk: roughly 1 in 8 men
• 5-year survival rate: nearly 100% for localized/regional disease; 32% for distant metastasis
• More than 3.3 million men in the U.S. are living with prostate cancer

Risk Factors

Non-Modifiable

• Age — risk rises sharply after 50; most cases diagnosed after 65
• Race/ethnicity — African American men have the highest incidence and mortality rates; Asian men have the lowest
• Family history — having a father or brother with prostate cancer doubles the risk
• Genetic mutations — BRCA1/2 mutations significantly increase risk of aggressive prostate cancer

Modifiable

• Diet high in saturated fat and red meat
• Obesity — associated with more aggressive disease and worse outcomes
• Low vitamin D levels — consistently linked to higher prostate cancer risk
• Dairy consumption — high calcium intake may suppress vitamin D activation
• Sedentary lifestyle
• Chronic inflammation — prostatitis may increase cancer risk

Symptoms

Early prostate cancer typically causes no symptoms. As the disease progresses, symptoms may include:

• Frequent urination, especially at night (nocturia)
• Difficulty starting or stopping urination
• Weak or interrupted urine flow
• Burning or pain during urination
• Blood in urine or semen
• Painful ejaculation
• Persistent pain in the back, hips, or pelvis (may indicate metastasis)

Note: Many of these symptoms are also caused by benign prostatic hyperplasia (BPH) — a non-cancerous enlargement of the prostate. Medical evaluation is essential to distinguish between the two.

Screening: The PSA Debate

The PSA (prostate-specific antigen) blood test is the primary screening tool for prostate cancer. PSA is a protein produced by both normal and cancerous prostate cells; elevated levels may indicate cancer, BPH, or prostatitis.

Screening recommendations vary:

• American Cancer Society: Discuss screening at age 50 for average-risk men; 45 for high-risk (African American men, first-degree relative with prostate cancer before 65); 40 for very high-risk (more than one first-degree relative)
• USPSTF: Recommends shared decision-making for men 55–69; does not recommend routine screening for men 70+

The controversy stems from overdiagnosis and overtreatment — many prostate cancers are slow-growing and may never cause harm, yet treatment carries significant side effects. This is why active surveillance has become a standard option for low-risk disease.

Staging and Grading

• Stage I–II: Localized to the prostate
• Stage III: Locally advanced (may involve seminal vesicles or nearby tissue)
• Stage IV: Metastatic (lymph nodes, bones, or distant organs)

The Grade Group (1–5, based on Gleason score) is equally important: Grade Group 1 (Gleason 6) is low-risk; Grade Group 5 (Gleason 9–10) is very high-risk.

Conventional Treatment Options

• Active surveillance — monitoring without immediate treatment; appropriate for low-risk, slow-growing cancers
• Radical prostatectomy — surgical removal of the prostate; robotic-assisted (da Vinci) is now standard
• Radiation therapy — external beam radiation (IMRT, SBRT) or brachytherapy (radioactive seed implants)
• Androgen deprivation therapy (ADT) — reduces testosterone to starve hormone-sensitive cancer; used for advanced disease or combined with radiation
• Chemotherapy — docetaxel and cabazitaxel for castration-resistant prostate cancer (CRPC)
• Targeted therapy — PARP inhibitors (olaparib, rucaparib) for BRCA-mutated CRPC
• Immunotherapy — sipuleucel-T (Provenge), a personalized cancer vaccine; pembrolizumab for MSI-H tumors
• Bone-targeted therapy — radium-223 (Xofigo) for bone metastases; denosumab and zoledronic acid for bone health

The Androgen-Testosterone Connection

Prostate cancer cells are often androgen-sensitive — they rely on testosterone and dihydrotestosterone (DHT) to grow. This is why ADT (which suppresses testosterone) is a cornerstone of advanced prostate cancer treatment.

However, the relationship is nuanced. The saturation model suggests that prostate cancer growth is maximally stimulated at relatively low testosterone levels, and that higher testosterone does not necessarily accelerate cancer growth. This has implications for testosterone replacement therapy decisions in men with treated prostate cancer — a topic requiring individualized discussion with a urologist or oncologist.

Evidence-Based Integrative Strategies

🥦 Dietary Approaches

• Tomatoes and lycopene — lycopene (the red pigment in tomatoes) is associated with reduced prostate cancer risk in multiple studies; cooked tomatoes (tomato sauce, paste) have higher bioavailability
• Cruciferous vegetables — sulforaphane from broccoli has shown anti-proliferative effects on prostate cancer cells in clinical trials
• Green tea (EGCG) — inhibits androgen receptor signaling and promotes apoptosis in prostate cancer cells
• Pomegranate juice — clinical trials show pomegranate extract can slow PSA doubling time in men with recurrent prostate cancer
• Soy isoflavones — genistein and daidzein may inhibit prostate cancer cell growth; Asian populations with high soy intake have lower prostate cancer rates
• Limit dairy and saturated fat — associated with more aggressive disease

🌿 Key Nutraceuticals

🏃 Lifestyle Factors

• Exercise — vigorous exercise (3+ hours/week) associated with 61% lower risk of prostate cancer death; particularly important during and after ADT to preserve muscle mass and bone density
• Stress reduction — chronic stress elevates cortisol, which can promote androgen-independent cancer growth
• Sleep optimization — melatonin suppression from poor sleep may accelerate prostate cancer progression
• Maintain healthy weight — obesity is associated with higher-grade disease and worse surgical outcomes

Managing ADT Side Effects Integratively

Androgen deprivation therapy causes significant side effects that integrative strategies can help address:

• Hot flashes — acupuncture, black cohosh, venlafaxine
• Bone loss — weight-bearing exercise, calcium, vitamin D3, vitamin K2
• Muscle loss and fatigue — resistance training, protein optimization, creatine
• Cognitive effects — omega-3s, lion's mane mushroom, sleep hygiene
• Cardiovascular risk — Mediterranean diet, exercise, CoQ10
• Depression and mood — exercise, social support, adaptogenic herbs (ashwagandha)

Repurposed Compounds & Emerging Investigational Approaches

A growing number of integrative and functional medicine practitioners are exploring the potential of repurposed compounds — medications originally developed for other conditions — as adjunctive tools in cancer support. The following compounds have generated significant interest based on preclinical data, mechanistic rationale, and anecdotal reports from patients and clinicians. This section is strictly educational and does not constitute medical advice or a treatment recommendation. Individuals interested in these approaches should work with a qualified, integrative-minded physician.

🔬 Antiparasitic Agents

💊 Low Dose Naltrexone (LDN)

Low Dose Naltrexone (typically 1.5–4.5 mg taken at bedtime) works through a fundamentally different mechanism than standard naltrexone. At low doses, it transiently blocks opioid receptors, triggering a rebound upregulation of the body's endogenous opioid system — specifically the OGF (opioid growth factor) – OGFr (OGF receptor) axis, which plays a direct role in regulating cell proliferation.

• Preclinical and clinical evidence suggests LDN may slow tumor growth by upregulating OGF-mediated inhibition of DNA synthesis
• LDN also modulates microglial and immune function, reducing pro-tumor inflammatory signaling (TLR4 pathway)
• Dr. Bernard Bihari (the pioneer of LDN) documented numerous anecdotal cancer responses in his clinical practice
• Dr. Burt Berkson has published case reports of LDN combined with alpha-lipoic acid producing remarkable outcomes in pancreatic and other cancers
• Dr. Paul Marik's FLCCC cancer protocols include LDN as a standard adjunctive recommendation
• A dedicated hub of LDN research is maintained at LDNResearchTrust.org and LowDoseNaltrexone.org

LDN is generally well-tolerated, inexpensive, and available via compounding pharmacy with a prescription. It must not be taken with opioid medications.

🌿 CBD & Full Extract Cannabis Oil (FECO)

Cannabinoids — particularly CBD (cannabidiol) and the full spectrum of compounds in FECO — interact with the body's endocannabinoid system (ECS) through CB1 and CB2 receptors, which are expressed on many cancer cell types including prostate cancer cells.

• CB2 receptor activation has been shown to induce apoptosis and inhibit migration in prostate cancer cell lines (British Journal of Pharmacology, Sarfaraz et al., 2008)
• CBD has demonstrated anti-proliferative, pro-apoptotic, and anti-angiogenic effects in preclinical prostate cancer models
• FECO (Full Extract Cannabis Oil) — sometimes called RSO (Rick Simpson Oil) — contains the full spectrum of cannabinoids, terpenes, and flavonoids, which may produce synergistic "entourage effects" beyond isolated CBD
• Dr. Dustin Sulak (Healer.com) is among the most prominent integrative physicians documenting cannabinoid use in oncology support, emphasizing individualized dosing and full-spectrum formulations
• THC-containing formulations may require legal consideration depending on jurisdiction

Cannabinoid use during active cancer treatment should be discussed with an oncologist, particularly regarding potential interactions with chemotherapy metabolism (CYP450 pathways).

🦠 Repurposed Antibiotics — Mitochondrial Targeting

An emerging and mechanistically compelling area of research involves the use of certain antibiotics — particularly those that target mitochondrial ribosomes — as potential cancer stem cell (CSC) inhibitors. Cancer stem cells are believed to drive tumor recurrence and treatment resistance.

• Doxycycline and azithromycin have been shown to inhibit mitochondrial biogenesis in cancer stem cells, effectively "starving" them of energy production
• Groundbreaking research by Dr. Michael Lisanti and Dr. Federica Sotgia (University of Salford) demonstrated that doxycycline selectively targets cancer stem cells across multiple tumor types, including prostate cancer, with minimal effect on normal cells
• Dr. Marco Fiorillo has published extensively on the mitochondrial targeting hypothesis and antibiotic repurposing in oncology
• Dr. Peter McCullough has discussed repurposed drug frameworks broadly, emphasizing the importance of early, multi-drug integrative approaches
• A 2017 paper in Oncotarget (Lamb et al.) demonstrated that doxycycline reduced cancer stem cell populations by up to 90% in certain models

Antibiotic use carries considerations around microbiome disruption and resistance; any use in a cancer-support context should be supervised by a physician familiar with this literature.

🧬 The Functional 13 Protocol: A Practitioner-Informed Integrative Stack

The Functional 13 Protocol is an integrative support framework built around 13 compounds — a combination of repurposed antiparasitic agents, nutraceuticals, and immune modulators — that have individually demonstrated preclinical or mechanistic relevance to cancer biology. While the protocol is not a clinical trial and makes no treatment claims, it represents a synthesis of the most-discussed compounds in integrative and functional oncology circles, several of which overlap directly with the repurposed drug frameworks championed by the FLCCC Alliance and other integrative practitioners.

Below is an educational overview of each compound and its proposed mechanistic relevance to prostate cancer specifically.

🔗 How Functional 13 Complements the Broader Repurposed Drug Framework

What makes the Functional 13 stack particularly notable from an integrative standpoint is how its components address multiple hallmarks of cancer simultaneously:

• Metabolic disruption — Fenbendazole, liposomal vitamin C, and green tea extract all target cancer cell energy metabolism through different pathways (glycolysis, OxPhos, HIF-1α)
• Immune activation — Turkey tail, lactoferrin, ivermectin, and CBD collectively support NK cell activity, macrophage function, and immunogenic cell death
• Hormone pathway modulation — Zinc, curcumin, vitamin D3, and green tea EGCG all interact with androgen receptor signaling — directly relevant to prostate cancer's hormone-driven biology
• Anti-metastatic support — Modified citrus pectin (galectin-3 inhibition) and CBD (anti-migration) address the spread mechanisms that make prostate cancer dangerous
• Liver & detox support — Milk thistle and black seed oil protect hepatic function, ensuring the body can process and eliminate both cancer metabolites and the compounds themselves
• Synergistic amplification — Ivermectin's P-glycoprotein inhibition and piperine's bioavailability enhancement mean the stack is designed to make each component more effective

This multi-target, low-toxicity philosophy aligns with the frameworks promoted by Dr. Paul Marik (FLCCC), Dr. Peter McCullough, and integrative oncologists who argue that repurposed, off-patent compounds deserve serious investigation as adjuncts — not replacements — for standard care.

As with all integrative approaches discussed in this article, the Functional 13 Protocol is presented here for educational purposes only. No treatment claims are made. Individuals should consult a qualified integrative physician before beginning any multi-compound protocol, particularly alongside conventional cancer treatment.

💊 Additional Repurposed Pharmaceuticals — Prostate-Specific Evidence

Beyond the Functional 13 stack, the following repurposed compounds have specific mechanistic or clinical relevance to prostate cancer biology and are increasingly discussed in integrative oncology protocols.

⚗️ Metabolic Targeting: Glutamine & the Prostate Cancer Energy Landscape

Prostate cancer cells — particularly in castration-resistant states — are highly dependent on glutamine as a secondary fuel source when glucose metabolism is disrupted. Targeting glutamine metabolism is therefore a logical complement to the glucose-disrupting compounds already in the Functional 13 stack.

• Glutamine dependence — prostate cancer cells use glutamine to fuel the TCA cycle, synthesize nucleotides for rapid DNA replication, and maintain redox balance via glutathione production
• EGCG (green tea extract) — already in Functional 13; suppresses glutamine transporter ASCT2, reducing glutamine uptake into cancer cells
• Berberine — inhibits glutamine-driven mTORC1 activation; overlaps with metformin on AMPK pathway; consider as an add-on to the Functional 13 stack for CRPC specifically
• CBD — already in Functional 13; reduces glutamine synthetase activity in cancer cell lines
• Dietary strategy — reducing dietary glutamine (limiting processed meat, whey protein, and MSG-heavy foods) may complement supplemental approaches; Dr. Thomas Seyfried advocates combining glucose and glutamine restriction as a metabolic cancer therapy framework
• DON (6-diazo-5-oxo-L-norleucine) — a glutamine antagonist with significant preclinical anti-tumor activity; being revisited in modified prodrug forms (DRP-104) to reduce GI toxicity; not yet widely available but worth monitoring in the research literature

Glutamine targeting is most relevant in men with castration-resistant or metastatic prostate cancer, where androgen deprivation has already shifted the tumor's metabolic dependencies. Always discuss metabolic interventions with a physician familiar with oncology nutrition.

📋 Practitioner Resources & Further Reading:

• FLCCC Alliance Cancer Protocols: covid19criticalcare.com
• LDN Research Trust: ldnresearchtrust.org
• Dr. Dustin Sulak / Cannabinoid Medicine: healer.com
• Dr. Burt Berkson — Alpha Lipoic Acid + LDN case reports: published in Integrative Cancer Therapies
• Lisanti et al. — Doxycycline & cancer stem cells: Oncotarget, 2017
• Juarez et al. — Ivermectin anti-tumor review: Pharmacological Research, 2020
• Hua et al. — Niclosamide & AR-V7: Clinical Cancer Research, 2014
• Sarfaraz et al. — Cannabinoids & prostate cancer: British Journal of Pharmacology, 2008

Conclusion

Prostate cancer is a disease of nuance — not all diagnoses require aggressive treatment, and not all men face the same risk. What is clear is that lifestyle, diet, and targeted supplementation play a meaningful role in both prevention and support during treatment. Whether you are focused on reducing risk, navigating active surveillance, or supporting recovery after treatment, an integrative approach grounded in evidence can make a real difference.

This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.

References

• Siegel RL et al. (2023). Cancer Statistics. CA: A Cancer Journal for Clinicians.
• Giovannucci E et al. (2002). A prospective study of tomato products, lycopene, and prostate cancer risk. JNCI.
• Ornish D et al. (2005). Intensive lifestyle changes may affect the progression of prostate cancer. Journal of Urology.
• Kenfield SA et al. (2011). Physical activity and survival after prostate cancer diagnosis. Journal of Clinical Oncology.
• Pantuck AJ et al. (2006). Phase II study of pomegranate juice for men with rising PSA. Clinical Cancer Research.
• Dogra N et al. (2019). Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death. Scientific Reports.
• Juarez M et al. (2020). Ivermectin as an antitumor agent. Pharmacological Research.
• Hua H et al. (2014). Niclosamide inhibits androgen receptor variants. Clinical Cancer Research.
• Sarfaraz S et al. (2008). Cannabinoids for cancer treatment. British Journal of Pharmacology.
• Lissoni P et al. (1997). Melatonin and cancer. British Journal of Cancer.
• Skrott Z et al. (2017). Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature.
• Margel D et al. (2011). Metformin use and all-cause and prostate cancer-specific mortality. Journal of Clinical Oncology.
• Guess BW et al. (2003). Modified citrus pectin in increasing PSA doubling time. Prostate Cancer and Prostatic Diseases.
• Standish LJ et al. (2008). Trametes versicolor mushroom immune therapy in breast cancer. Journal of the Society for Integrative Oncology.